Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Shree Ganesh Biotech (India) Ltd

₹ 0.694.55%
07 Jan 4:01 p.m. – close price
🔗shreeganeshbiotech.clubâ€ĸBSE: 539470â€ĸNSE:
Market Cap₹ 27.5 Cr.
Current Price₹ 0.69
High / Low₹ 1.15
Stock P/E172
Book Value₹ 1.60
Dividend Yield0.00 %
ROCE0.62 %
ROE0.44 %
Face Value₹ 1.00
Sales₹ 19.6 Cr.
OPM-7.36 %
Mar Cap₹ 27.5 Cr.

ABOUT

Incorporated in 1982, Shree Ganesh Biotech Ltd is in the trading of seeds and bhushi

KEY POINTS

Business Overview:[1]Company does business of production, processing and marketing of high quality hybrid seeds for different crops like corn, sunflower, cotton, paddy, grain sorghum, etc., micronutrients, bio products, etc.

Also present in buckets:
Red Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Anthem Bioscienc655.5079.5836847.930.00173.437.10550.034.7828.501844.5536.40451.51173.4313.3717.350.04
2.Advanced Enzyme311.8023.673488.751.6644.7431.98184.5326.3013.11706.7330.75147.3943.332.358.540.02
3.Genesis IBRC87.27–113.460.00-0.06-101.640.00-100.0051.620.00–-0.23-0.0613.5949.860.00
4.Vivo Bio Tech31.5017.0269.620.000.87-83.3713.118.899.0450.1242.824.090.870.722.680.58
5.Shree Ganesh Bio0.69171.9127.510.000.01-96.880.77-61.110.6219.57-7.360.160.010.430.410.02
6.Genomic Valley25.1676.867.690.000.00-100.000.09-57.1411.840.6628.790.100.001.968.290.00
–Median: 3 Co.311.851.623488.750.044.747.1184.534.7828.5706.7333.58147.3943.3313.3717.350.02

Quarterly Results

Standalone figures in ₹ crores

Dec 2022Dec 2023Dec 2024Jun 2023Jun 2024Jun 2025Mar 2023Mar 2024Mar 2025Sep 2022Sep 2023Sep 2024Sep 2025
Sales
12.074.1214.418.253.561.387.983.783.0121.764.121.980.77
Expenses
11.804.0313.948.103.691.478.464.304.4320.574.041.961.17
Operating Profit
0.270.090.470.15-0.13-0.09-0.48-0.52-1.421.190.080.02-0.40
Other Income
-0.00-0.000.30-0.000.370.420.581.060.470.01-0.000.300.41
Profit before tax
0.270.090.770.150.240.330.100.54-0.951.200.080.320.01
Tax %
-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%-0.00%
Net Profit
0.270.090.770.150.240.330.100.54-0.951.200.080.320.01
EPS in Rs
0.010.000.020.000.010.010.000.01-0.020.030.000.010.00

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
2.261.682.128.547.865.872.4717.2172.6462.4520.2822.9619.57
Expenses
1.841.171.474.784.364.082.2316.5069.1960.3020.4824.0121.01
Operating Profit
0.420.510.653.763.501.790.240.713.452.15-0.20-1.05-1.44
Other Income
0.000.000.040.000.000.000.00-0.280.050.561.061.441.60
Interest
0.040.070.070.030.000.000.000.000.000.000.000.000.00
Depreciation
0.210.100.070.000.000.000.000.000.000.000.000.000.00
Profit before tax
0.170.340.553.733.501.790.240.433.502.710.860.390.16
Net Profit
0.170.340.543.733.501.790.240.322.532.040.620.280.16
EPS in Rs
0.050.090.151.010.950.040.010.010.060.050.020.010.01
Dividend Payout %
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%–

Compounded Profit Growth

10 Years:-2%
5 Years:3%
3 Years:-52%
TTM:-87%

Compounded Sales Growth

10 Years:30%
5 Years:56%
3 Years:-32%
TTM:46%

Return on Equity

10 Years:4%
5 Years:2%
3 Years:2%
Last Year:0%

Stock Price CAGR

10 Years:%
5 Years:-35%
3 Years:-21%
1 Year:-32%

Balance Sheet

Standalone figures in ₹ crores

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
1.831.831.831.831.8319.9319.9319.9319.9339.8639.8639.8639.86
Reserves
2.062.412.9417.5421.0437.3137.5437.8640.3922.4923.1223.3923.73
Borrowings
0.330.610.500.060.190.190.190.19-0.00-0.00-0.00-0.001.43
Other Liabilities
0.080.120.030.013.306.667.0616.6433.2417.1810.640.240.12
Total Liabilities
4.304.975.3019.4426.3664.0964.7274.6293.5679.5373.6263.4965.14
Fixed Assets
2.382.402.32-0.00-0.000.01-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Gross Block
3.212.922.920.000.000.010.010.010.010.010.010.01–
Accumulated Depreciation
0.830.520.600.000.000.000.000.000.000.000.000.01–
CWIP
-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Investments
0.210.210.21-0.00-0.00-0.00-0.003.063.22-0.00-0.009.159.15
Other Assets
1.712.362.7719.4426.3664.0864.7271.5690.3479.5373.6254.3455.99
Total Assets
4.304.975.3019.4426.3664.0964.7274.6293.5679.5373.6263.4965.14

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
0.19-0.07-0.04-12.942.23-0.50-1.012.363.5710.5410.16-10.21
Cash from Investing Activity
-0.33-0.11-0.002.53-2.36-32.070.99-2.36-3.37-10.09-10.219.80
Cash from Financing Activity
0.140.28-0.1110.420.1332.58-0.00-0.00-0.19-0.00-0.00-0.00
Net Cash Flow
-0.000.10-0.160.02-0.000.01-0.020.010.010.44-0.05-0.41

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
92.06260.71456.25384.23627.841,191.383,072.21601.05220.54112.9859.390.00
Inventory Days
298.37483.240.000.000.000.000.000.000.000.000.0046.59
Days Payable
20.2846.27–––––––––0.00
Cash Conversion Cycle
370.15697.69456.25384.23627.841,191.383,072.21601.05220.54112.9859.3946.59
Working Capital Days
251.95310.68380.50383.81475.99779.122,036.32249.2053.7112.80-132.1150.08
ROCE %
5.17%9.04%12.25%30.45%16.47%4.45%0.42%1.23%5.92%4.42%1.37%0.62%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Promoters
––––––––––––
FIIs
2.42%2.42%2.42%2.17%2.17%1.42%1.42%1.42%1.42%1.42%1.42%1.42%
DIIs
––––––––––––
Public
97.57%97.57%97.57%97.83%97.84%98.57%98.58%98.57%98.58%98.58%98.58%98.58%

* The classifications might have changed from Sep'2022 onwards.ℹī¸

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Shree Ganesh Bio-Tech announces trading window closure for Q4 FY26 results

17th March 2026, 11:39 pm

Shree Ganesh Biotech (India) Ltd: Discloses No Unutilized Proceeds from Past Fundraisings as of Dec 31, 2025

29th January 2026, 10:01 pm

Shree Ganesh Bio-Tech (India) Limited: Un-audited Q3 FY26 Financial Results Announced

29th January 2026, 9:57 pm

Shree Ganesh Bio-Tech Reports Steep Revenue Decline YoY for Q3 FY26; Profit Drops Significantly

29th January 2026, 9:43 pm

Shree Ganesh Bio-Tech Announces Board Meeting on Jan 29, 2026, to Approve Q3 & 9M FY26 Unaudited Financial Results

19th January 2026, 11:27 pm

Documents

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

2d - RTA certificate for quarter ended 31 Dec 2025; no physical demat requests.

Closure of Trading Window

20 Dec - Trading window closed Jan 1, 2026 until 48 hours after unaudited Q4 (31 Dec 2025) results.

Disclosure Under Regulation 32(1) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015

8 Nov 2025 - Confirms no unutilised proceeds from issue as of 30 September 2025.

Regulations 30, 33 And Other Applicable Provisions Of The SEBI (LODR) Regulations, 2015

8 Nov 2025 - Approved unaudited Q2/H1 results: six-month income Rs297.65L, net profit Rs34.11L, EPS Rs0.01.

Board Meeting Outcome for Outcome Of The Board Meeting Of The Board Held On 8Th November 2025.

8 Nov 2025 - Board approved Q2/H1 results: H1 revenue Rs297.65 lakh, H1 net profit Rs34.11 lakh (30 Sep 2025).

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from bse)

Financial Year 2012

(from bse)

Credit Ratings

No credit ratings.

Concalls

No concalls.

Stock Analysis

Description

  1. Shree Ganesh Bio-Tech (India) Limited is involved in the production, processing, and marketing of hybrid seeds, micronutrients, and bio products for various crops.

Key Growth Triggers

  1. The company operates in the agricultural inputs sector, focusing on seeds and bio-products. However, its growth is severely hampered by reported working capital scarcity, which leads to a lack of operational activity, contradicting stated sales figures.

Order Book

  1. Currently no data available for Order Book.

Key Red Flags

  1. Management's statement regarding working capital scarcity directly contradicts reported sales, indicating potential operational issues or data discrepancies.
  2. Recent financial performance shows significant declines in revenue and net profit, with EPS falling to very low levels (e.g., ₹0.01 in FY25).
  3. The company has a history of not paying dividends despite periods of reported profits, which may deter income-seeking investors.

Key Dates To Watch

  1. January 5, 2026: Submission of SEBI compliance certificate for the quarter ended December 31, 2025.
  2. September 26, 2025: 15th Annual General Meeting held.
  3. November 8, 2025: Board meeting to approve Q2/H1 FY26 results.

Corporate Announcements

17th Mar 26
Impact Rating: 6
Shree Ganesh Bio-Tech (India) Limited has announced a closure of its trading window from April 1, 2026. This blackout period will remain in effect until 48 hours following the declaration of its audited financial results for the quarter and year ending March 31, 2026.
29th Jan 26
Impact Rating: 2
Shree Ganesh Biotech (India) Limited has submitted a disclosure stating that no funds remain unutilized from any past public issue, rights issue, preferential issue, or QIP.
29th Jan 26
Impact Rating: 4
Shree Ganesh Bio-Tech (India) Limited board approved un-audited financial results for the quarter and nine months ended December 31, 2025.
29th Jan 26
Impact Rating: 2
Shree Ganesh Bio-Tech reported unaudited Q3 FY26 financial results on Jan 29, 2026, showing a sharp decline in revenue and profit compared to the previous year.
19th Jan 26
Impact Rating: 3
Shree Ganesh Bio-Tech (India) Limited has announced a Board meeting on January 29, 2026. The agenda includes the approval of unaudited financial results for the third quarter and the nine months ending December 31, 2025.